VCIM
MLYS icon

Velan Capital Investment Management’s Mineralys Therapeutics MLYS Stock Holding History

Velan Capital Investment Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Hold
11,000
– – 0.18% 31
2026
Q1 		$298K Sell
11,000
-140,000
-93% -$4.11M 0.19% 31
2025
Q4 		$5.48M Sell
151,000
-24,600
-14% -$987K 3.18% 8
2025
Q3 		$6.66M Buy
175,600
+1,000
+0.6% +$21.6K 6.25% 6
2025
Q2 		$2.36M Buy
174,600
+24,000
+16% +$348K 2.33% 14
2025
Q1 		$2.39M Buy
+150,600
New +$1.73M 2.46% 13

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Velan Capital Investment Management's MLYS Position: Q2 2026 in Review

Velan Capital Investment Management held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 11,000 shares worth $297K. The position accounts for 0.18% of the portfolio, ranked #31.

Velan Capital Investment Management first reported a position in MLYS in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.66M in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Velan Capital Investment Management held 11,000 shares of Mineralys Therapeutics worth $297K as of Q2 2026.
  • Velan Capital Investment Management left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up 0.18% of Velan Capital Investment Management's portfolio in Q2 2026, its #31 holding.
  • Velan Capital Investment Management first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Velan Capital Investment Management's Mineralys Therapeutics position peaked at $6.66M in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Velan Capital Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.